Skip to Main Content

GSK said Friday that its RSV vaccine showed “statistically significant and clinically meaningful efficacy” in adults over 60 in a 25,000-volunteer randomized trial taking place in 17 countries.

The company said that it plans to submit the data to regulators, including the Food and Drug Administration, in the second half of the year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment